BioWorld

Oct. 8, 2009

MannKind Bulls, Bears Face off in Wake of Afresa Partner Delay

News that MannKind Corp. will not achieve its goal of signing a partnership this year for inhaled insulin product Afresa polarized the company's bullish backers and its bearish detractors. (BioWorld Today) Read More

Epizyme's $32M to Fuel HMTs; Nobel Winner Helps the Push

Androxal Gives Repros Relief; Proellex, Cash Troubles Loom

Allos Expands Offering, Adds $100M for Folotyn Launch Prep

MIT Biochemist, Stem-Cell Ace Among National Medal Winners

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...